• Global drug spending to hit $1.4 trillion in 2020: IMS

    Global spending on medicines will reach $1.4 trillion in 2020, driven by increased healthcare access in emerging markets and high-priced new drugs for cancer and other diseases, according to a forecast by IMS Health released on Wednesday. That is up from about $1.07 trillion this year, representing a compound annual growth rate of 4 to 7 percent over the next five years, the "Global Medicines Use in 2020" report compiled by IMS Institute for Healthcare Informatics found. Some 225 new drugs will


  • Lessons from Australia and China’s Healthcare Cooperation: What Can Canadian Firms Learn?

    NAI500 Comments: i. The Chinese government is heavily focused on the health of its citizens as shown by its decision to build 7,500 public hospitals through the private sector over the next decade. ii. China’s health challenges include significantly high rates of smoking, high pollution levels, and a rapidly aging population. iii. Given China’s healthcare challenges, Canadian healthcare developers should target cancer treatment, heart disease treatment, and age related solutions. iv. The cit


  • South Korea's Genexine expands into China in Tasgen deal for up to $100M

    South Korean biotech Genexine Inc. licensed out three of its compounds for $100 million to a Chinese drug developer, exploring the Asian market for next-generation long-acting growth hormone treatments. Clinical-stage Genexine (KOSDAQ:095700) signed a licensing and technology transfer agreement with China's Tasgen, a subsidiary of Tasly Pharmaceutical Group Co. Ltd. (SH:600535). Under the deal reached this week, Genexine will grant the China rights for three compounds, GX-H9, GX-G6 and GX-G3, to Tasgen i


Investment Opportunities

Opportunities

Potash in another mining friendly region other than Saskatchewan

With the junior mining sector struggling in the past few years, it is difficult for inv... Full Story

The hidden gems in CSE

Breaking News

Chinese Pharmaceutical Firm GZ Bailing Group Pharm. Agrees to Back Herbal Medicine Maker

Chinese pharmaceutical firm GZ Bailing Group Pharm. Co. [SHE:002424] said in a statement that it will boost an herbal medicine company’s competitiveness by investing in it. T...

Celltrion Envisions Remsima Plant in China

WuXi Biologics guns for $500M Hong Kong IPO

Frontline BioVentures, WuXi Healthcare To Merge, Creating $800M Fund

WuXi NextCODE In Hunt For $200 Million In Venture Capital

Select Companies

Diamedica Inc

Diamedica Inc is a development stage biopharmaceutical company. The Company is engaged in the dis...

Trxade Group Inc

Trxade Group Inc, formerly Xcellink International Inc. develops patented business process that pr...

Kane Biotech Inc.

Kane Biotech is a Canadian-based biotechnology company engaged in the development and commerciali...

Experts Column

Top 10 Developments that Investors should pay extra attention in the new year

Gilber Chan, the President of NAI500, presents the latest speech of 2016 investment strategy on Global Chinese Financial Forum - Vancouver Conference 2016: The Top 10 Developments...

China could boost growth with supply, property reforms, tax cuts, HSBC says

China's policymakers still have ammunition to counter the mainland's slowing economy, including supply-side reforms and subsidized housing, HSBC said. In a note released Tu...

Here’s how to play Chinese stocks in 2016?

Consumer staples and services, health care, software and auto stocks are Henderson Global Investors' top Chinese stock picks for 2016 — but don't get your hopes up for a...

G-20 sticks to 2% growth goal despite headwinds

The leaders of the world's largest economies stuck to a goal of lifting their collective output by an extra 2 percent by 2018, even though growth remains uneven and weaker than expect...

Why isn't the yuan rising despite IMF support?

The renminbi's status as a global reserve currency may be effectively guaranteed following formal backing by International Monetary Fund (IMF) staff, according to economists, but trad...

Press Release

VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update

today announced financial results for the quarter ended March 31, 2017 and provided a business update. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "...

A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays

 today announced the publication of a research paper entitled "Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer". The study was...

Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success

today highlighted two additional works involving its lead drug, apabetalone, one recently published by third party academics and one in the form of a patent application by Pfizer Inc. (Pf...

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results

Naturally Splendid Reports First Quarter Sales for 2017

Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial

CohBar, Inc. Announces First Quarter 2017 Financial Results

Luminor Medical Technologies Acquiring Exclusive Canadian & Jamaican Licenses for Cannabis Products - Video Available on Investmentpitch.com

DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM)

Daily Top Performing Life Science Stocks
         Company Name Symbol Price Change Vol(k) Day's Range Contact
1 AEterna Zentaris Inc NASDAQ:AEZS 1.122
0.162 (16.84%)
1616571 0.9501 - 1.2100
2 MEI Pharma Inc NASDAQ:MEIP 2.150
0.180 (9.13%)
613785 1.9500 - 2.1500
3 Cellular Biomedicine Group Inc NASDAQ:CBMG 5.900
0.400 (7.27%)
24598 5.70 - 6.05
4 Avita Medical Ltd OTCMKTS:AVMXY 1.480
0.090 (6.47%)
8320 1.34 - 1.48
5 Titan Medical Inc TSX:TMD 0.360
0.020 (4.35%)
101670 0.35 - 0.37
6 GTx Inc NASDAQ:GTXI 3.510
0.140 (4.15%)
3022 3.36 - 3.53
7 OncoGenex Pharmaceuticals Inc NASDAQ:OGXI 0.370
0.015 (4.11%)
22627 0.3502 - 0.3700
8 Durect Corp NASDAQ:DRRX 1.308
0.048 (3.84%)
466465 1.2500 - 1.3100
9 Windtree Therapeutics Inc NASDAQ:WINT 0.950
0.030 (3.26%)
4789 0.91 - 0.95
10 TG Therapeutics Inc NASDAQ:TGTX 12.269
0.369 (3.10%)
406760 11.800 - 12.500
11 TrovaGene Inc NASDAQ:TROV 0.710
0.020 (2.84%)
15770 0.7014 - 0.7400
12 Supernus Pharmaceuticals Inc NASDAQ:SUPN 35.100
0.950 (2.78%)
120598 34.35 - 35.45
13 CohBar, Inc. TSXV:COB.U 1.950
0.050 (2.63%)
300 1.95 - 1.95
14 Cardiome Pharma Corp NASDAQ:CRME 4.230
0.100 (2.42%)
11830 4.15 - 4.25
15 Sunesis Pharmaceuticals Inc NASDAQ:SNSS 3.140
0.070 (2.28%)
6816 3.03 - 3.14
More